Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GCK | P35557 | 9/20 | 0.48 |
| ▸ | RARA | P10276 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1042324 | 1.00 | LMNA (0.49) | LMNAHPGDMEN1KMT2AGCK | |
| SCHEMBL1427137 | 0.90 | MEN1 (0.61) | MEN1KMT2AGCKRARARARB | |
| SCHEMBL1427108 | 0.88 | LMNA (0.54) | LMNAHPGDMEN1KMT2AGCK | |
| SCHEMBL2662217 | 0.88 | LMNA (0.54) | LMNAHPGDMEN1KMT2AGCK | |
| SCHEMBL12408453 | 0.88 | LMNA (0.54) | LMNAHPGDMEN1KMT2AGCK | |
| SCHEMBL1042436 | 0.88 | LMNA (0.54) | LMNAHPGDMEN1KMT2AGCK | |
| SCHEMBL4112699 | 0.87 | LMNA (0.46) | LMNAHPGDMEN1KMT2AGCK | |
| SCHEMBL1427055 | 0.87 | LMNA (0.46) | LMNAHPGDMEN1KMT2AGCK | |
| SCHEMBL13405027 | 0.86 | LMNA (0.52) | LMNAHPGDMEN1KMT2AGCK | |
| SCHEMBL2656262 | 0.85 | LMNA (0.56) | LMNAHPGDMEN1KMT2AGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943607-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-20090105214-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105214-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | GCK, GCKR, GK | LMNA 2213/4885HPGD 254/4885MEN1 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.